192 related articles for article (PubMed ID: 28112533)
1. Causal Effects of Intensive Lifestyle and Metformin Interventions on Cardiovascular Disease Risk Factors in Pre-Diabetic People: An Application of G-Estimation.
Salimi Y; Fotouhi A; Mohammad K; Mansournia N; Mansournia MA
Arch Iran Med; 2017 Jan; 20(1):55-59. PubMed ID: 28112533
[TBL] [Abstract][Full Text] [Related]
2. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
Goldberg RB; Temprosa M; Mele L; Orchard T; Mather K; Bray G; Horton E; Kitabchi A; Krakoff J; Marcovina S; Perreault L; White N;
Metabolism; 2016 May; 65(5):764-775. PubMed ID: 27085783
[TBL] [Abstract][Full Text] [Related]
3. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.
Ratner R; Goldberg R; Haffner S; Marcovina S; Orchard T; Fowler S; Temprosa M;
Diabetes Care; 2005 Apr; 28(4):888-94. PubMed ID: 15793191
[TBL] [Abstract][Full Text] [Related]
4. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
5. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
[TBL] [Abstract][Full Text] [Related]
6. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
Diabetes Prevention Program Research Group
Diabetes Care; 2012 Apr; 35(4):723-30. PubMed ID: 22442395
[TBL] [Abstract][Full Text] [Related]
7. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.
Goldberg RB; Temprosa M; Haffner S; Orchard TJ; Ratner RE; Fowler SE; Mather K; Marcovina S; Saudek C; Matulik MJ; Price D;
Diabetes Care; 2009 Apr; 32(4):726-32. PubMed ID: 19171717
[TBL] [Abstract][Full Text] [Related]
8. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.
Orchard TJ; Temprosa M; Goldberg R; Haffner S; Ratner R; Marcovina S; Fowler S;
Ann Intern Med; 2005 Apr; 142(8):611-9. PubMed ID: 15838067
[TBL] [Abstract][Full Text] [Related]
9. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
[TBL] [Abstract][Full Text] [Related]
10. The rationale, design, and baseline characteristics of PREVENT-DM: A community-based comparative effectiveness trial of lifestyle intervention and metformin among Latinas with prediabetes.
Perez A; Alos VA; Scanlan A; Maia CM; Davey A; Whitaker RC; Foster GD; Ackermann RT; O'Brien MJ
Contemp Clin Trials; 2015 Nov; 45(Pt B):320-327. PubMed ID: 26597415
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
Florez H; Temprosa MG; Orchard TJ; Mather KJ; Marcovina SM; Barrett-Connor E; Horton E; Saudek C; Pi-Sunyer XF; Ratner RE; Goldberg RB;
Diabetes Obes Metab; 2014 Apr; 16(4):326-33. PubMed ID: 24118860
[TBL] [Abstract][Full Text] [Related]
12. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program.
Goldberg RB; Mather K
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2077-90. PubMed ID: 22895669
[TBL] [Abstract][Full Text] [Related]
13. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
Ratner RE; Christophi CA; Metzger BE; Dabelea D; Bennett PH; Pi-Sunyer X; Fowler S; Kahn SE;
J Clin Endocrinol Metab; 2008 Dec; 93(12):4774-9. PubMed ID: 18826999
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.
Diabetes Prevention Program Research Group
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):866-75. PubMed ID: 26377054
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program.
Varga TV; Winters AH; Jablonski KA; Horton ES; Khare-Ranade P; Knowler WC; Marcovina SM; Renström F; Watson KE; Goldberg R; Florez JC; Pollin TI; Franks PW
Circ Cardiovasc Genet; 2016 Dec; 9(6):495-503. PubMed ID: 27784733
[TBL] [Abstract][Full Text] [Related]
16. Effect of metformin combined with lifestyle modification versus lifestyle modification alone on proinflammatory-oxidative status in drug-naïve pre-diabetic and diabetic patients: A randomized controlled study.
Bulatova N; Kasabri V; Qotineh A; Al-Athami T; Yousef AM; AbuRuz S; Momani M; Zayed A
Diabetes Metab Syndr; 2018 May; 12(3):257-267. PubMed ID: 29221717
[TBL] [Abstract][Full Text] [Related]
17. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes.
Apovian CM; Bergenstal RM; Cuddihy RM; Qu Y; Lenox S; Lewis MS; Glass LC
Am J Med; 2010 May; 123(5):468.e9-17. PubMed ID: 20399326
[TBL] [Abstract][Full Text] [Related]
18. The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program.
O'Brien MJ; Whitaker RC; Yu D; Ackermann RT
Prev Med; 2015 Aug; 77():125-30. PubMed ID: 26024851
[TBL] [Abstract][Full Text] [Related]
19. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Knowler WC; Barrett-Connor E; Fowler SE; Hamman RF; Lachin JM; Walker EA; Nathan DM;
N Engl J Med; 2002 Feb; 346(6):393-403. PubMed ID: 11832527
[TBL] [Abstract][Full Text] [Related]
20. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.
Hoeger KM; Kochman L; Wixom N; Craig K; Miller RK; Guzick DS
Fertil Steril; 2004 Aug; 82(2):421-9. PubMed ID: 15302293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
